20/20 Biolabs, Inc.
For the period ended Sep 16, 2026. Filed Sep 18, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 16, 2026 · Filed Sep 18, 2026
Use the contents to explore the available documents and sections.
Contents
PROXY STATEMENT
proxy statement, dated June 23, 2026, the relevant portions of which are incorporated herein by reference.
Proposal 3: The Company’s stockholders approved an amendment and restatement of the Company’s Second Amended and Restated Certificate of Incorporation to, among other things, increase the number of shares of common stock that the Company is authorized to issue from 50 million shares to 500 million shares. The votes regarding this proposal were as follows:
| Votes For | Votes Against | Abstentions |
|---|---|---|
| 3,028,609 | 1,155,607 | 72,621 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 18, 2026 | 20/20 BIOLABS, INC. | |
|---|---|---|
| /s/ Jonathan Cohen | ||
| Name: | Jonathan Cohen | |
| Title: | Chief Executive Officer |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.